Saudi Arabia’s biotechnology opportunity is no longer simply about selling innovative medicines into a growing healthcare system.

The bigger opportunity is being created around local manufacturing, clinical research, biologics, vaccines, genomics, cell and gene therapies, technology transfer and regional exports.

For companies evaluating Saudi Arabia in 2026, the important question is therefore not only:

“How large is the Saudi biotechnology market?”

It is:

“Which biotechnology capabilities is Saudi Arabia actively building, which companies are already positioned there, and where does the next commercial opportunity exist?”

That distinction matters for pharmaceutical companies, biotechnology companies, CDMOs, CROs, technology providers and investors planning expansion through 2035.

Saudi Arabia’s National Biotechnology Strategy provides a clear direction: develop end-to-end vaccine capabilities, build local biomanufacturing, expand genomics and increase the use of biotechnology to strengthen healthcare and economic development.

Saudi Arabia Biotechnology: The Numbers That Matter

Several official indicators demonstrate that this is becoming an execution-driven opportunity rather than a purely strategic ambition.

83% growth: SFDA reported an 83% increase in clinical-trial applications submitted for advanced therapies and biotechnology products in 2025 compared with 2024.

39% growth: Overall early-stage clinical trials increased by 39% during the same period.

$34+ billion: Invest Saudi identifies a target of more than $34 billion in combined GDP contribution from medical, industrial and agricultural biotechnology by 2040.

55,000+ jobs: The same government investment platform targets more than 55,000 direct and indirect biotechnology jobs by 2040.

$8.5 billion: MISA currently identifies Saudi Arabia’s pharmaceutical sector at approximately $8.5 billion and says the pharma and biotech sector is expected to grow at a 7.3% CAGR over the next six years.

SAR 8 billion: Saudi Arabia’s first gene and cell therapy manufacturing facility at KFSH&RC is projected to generate approximately SAR 8 billion in savings by 2030.

9% domestic demand: The same facility is expected to meet around 9% of domestic demand for advanced therapies by 2030.

These numbers reveal an important commercial pattern:

Saudi Arabia is moving from biotechnology consumption toward biotechnology capability creation.

What Is Driving Saudi Arabia’s Biotechnology Opportunity Through 2035?

The National Biotechnology Strategy identifies several strategic plays.

1. Vaccines and biological manufacturing

Saudi Arabia wants to develop end-to-end vaccine manufacturing capabilities for domestic self-sufficiency and future MENA exports.

For international vaccine manufacturers, this creates potential opportunities in:

• Technology transfer
• Fill-finish
• Drug substance manufacturing
• Cold-chain infrastructure
• Quality and regulatory services
• Local partnerships
• Regional export manufacturing

The National Biotechnology Strategy explicitly positions vaccine manufacturing as a strategic capability.

2. Biologics and biosimilars

Biologics are another major localization priority.

Saudi Arabia’s strategy calls for an end-to-end local biomanufacturing platform and greater biosimilar penetration to improve healthcare affordability and strengthen supply resilience.

This creates opportunities for:

Pharma companies → local production and commercialization

CDMOs → technology transfer and manufacturing

Biotech companies → development and clinical partnerships

Investors → manufacturing infrastructure and platform technologies

3. Genomics and precision medicine

Saudi Arabia also has a strategic interest in genomics.

The National Biotechnology Strategy calls for expansion of the national genomic database and analytics capabilities, with applications across prevention, diagnosis and personalized treatment.

This expands the opportunity beyond traditional drug manufacturing into:

• Genomic testing
• Bioinformatics
• AI-enabled drug discovery
• Precision medicine
• Population genomics
• Companion diagnostics
• Clinical data platforms

4. Cell and gene therapy

This could become one of the most commercially important areas through 2035.

In August 2025, SFDA approved Saudi Arabia’s first-of-its-kind Phase I clinical study of a locally developed CAR-T therapy for adults with relapsed/refractory CD19-positive acute lymphoblastic leukemia.

KFSH&RC has subsequently developed local CAR-T manufacturing capabilities.

Its facility is designed to produce up to 2,400 therapeutic doses annually by 2030, while future expansion includes gene-editing and additional advanced cell technologies.

KFSH&RC has also reported that locally manufactured CAR-T therapy reduced treatment costs from approximately SAR 1.3 million to around SAR 250,000 per patient, while reducing manufacturing time from approximately 28 days to 12–14 days.

That is more than a healthcare achievement.

It is a localization business case.

Saudi Arabia Biotechnology Competitive Landscape

For companies considering entry, understanding the competitive structure is more useful than simply counting biotechnology companies.

Saudi Arabia’s competitive environment is developing around four groups: government-backed platforms, healthcare/research institutions, local pharmaceutical manufacturers and international pharmaceutical companies.

Competitor / Organization	Strategic Position	Why It Matters
Lifera / PIF	Biopharma manufacturing & CDMO	Major localization platform across biologics, vaccines, advanced therapies and critical medicines
KFSH&RC	Advanced therapies & clinical research	Local CAR-T manufacturing and gene/cell therapy development
SaudiBio	Biopharmaceutical manufacturing	Important local manufacturing asset integrated into Lifera
Local pharmaceutical manufacturers	Generics, specialty pharma & manufacturing	Potential partners for commercialization and local production
Global pharma companies	Innovative medicines, partnerships & technology transfer	Increasing interest in Saudi localization
Research hospitals & universities	Clinical research, genomics & translational science	Important partners for clinical development and precision medicine

Lifera: The Competitor International CDMOs Need to Watch

Lifera is particularly important for companies evaluating the Saudi CDMO landscape.

The PIF-backed company describes its strategy around becoming a leading biopharma CDMO focused on advanced therapeutics and critical medicines, while developing cGMP manufacturing capacity, multi-omics capabilities, commercial partnerships and technology-transfer opportunities.

Lifera’s manufacturing strategy spans biologics, vaccines, drug-product manufacturing and other biopharmaceutical capabilities. Its stated ambition also includes serving global customers and creating a bridge between Saudi Arabia and international markets.

Commercial implication: An international CDMO entering Saudi Arabia may not simply compete with an empty local manufacturing ecosystem.

It may need to decide whether to:

Build → Partner → Acquire → License technology → Provide specialized capabilities around the existing ecosystem.

That is a much more important strategic question.

KFSH&RC: A Different Type of Biotechnology Competitor

KFSH&RC should not be viewed only as a hospital.

Its growing capabilities in gene and cell therapy place it closer to an integrated clinical + research + manufacturing platform.

The organization has already moved from importing CAR-T therapies toward local manufacturing and clinical application. KFSH&RC says it has treated more than 200 patients with CAR-T therapies manufactured abroad since 2020 before establishing local production.

This creates a competitive advantage around:

• Patient access
• Clinical expertise
• Translational research
• Manufacturing
• Advanced therapy trials
• Regulatory experience
• Real-world clinical data

For international advanced-therapy companies, KFSH&RC could therefore represent not only a healthcare customer but also a potential clinical and technology-development partner.

What Does the Competitive Landscape Mean for International Companies?

The opportunity is not the same for every entrant.

For global pharmaceutical companies

The question is increasingly:

Should we export products to Saudi Arabia, localize manufacturing, or establish a deeper R&D and commercial presence?

Companies that can combine innovative products with localization and technology-transfer strategies may have a stronger strategic position.

MISA has already highlighted localization of biologics, vaccines and cell and gene therapy as priority areas.

For biotech companies

The opportunity is different.

Biotech companies may need:

• Clinical development partners
• Hospital relationships
• Local investors
• Regulatory support
• Genomic infrastructure
• Manufacturing partners
• Regional commercialization

The growth in advanced-therapy clinical applications is an important signal that Saudi Arabia is building a more active clinical-development ecosystem.

For CDMOs

The question is not simply whether Saudi Arabia needs manufacturing.

It is:

Which modalities will require local capacity that existing players cannot fully provide?

Potential areas include:

• Viral vectors
• Cell therapy
• Gene therapy
• Biologics
• Vaccines
• Sterile fill-finish
• Advanced drug products
• Genomics and multi-omics

For CROs

The 83% increase in applications for advanced therapies and biotechnology products should be closely watched.

CRO opportunities can emerge across:

• Clinical trial management
• Regulatory consulting
• Patient recruitment
• Biomarker studies
• Data management
• Pharmacovigilance
• Real-world evidence
• Genomics
• Advanced therapy development

For investors

The strongest opportunities may not necessarily be in launching another biotech product.

They may exist in infrastructure and enabling technologies.

Examples include:

• Biomanufacturing
• Genomics
• Bioinformatics
• Clinical research
• Advanced therapy manufacturing
• Cold-chain infrastructure
• Regulatory technology
• Laboratory automation
• AI-enabled drug discovery

Saudi Arabia Biotechnology TAM, SAM and SOM: A Better Way to Calculate the Opportunity

A single top-down biotechnology number can be misleading because Saudi Arabia’s biotechnology strategy covers multiple industries.

A more useful commercial model is:

TAM

Total addressable opportunity across:

Biologics + vaccines + biosimilars + genomics + cell & gene therapy + biotech R&D + biomanufacturing + supporting services

SAM

Focus on capabilities aligned with Saudi Arabia’s current strategic priorities:

Biomanufacturing + biologics + vaccines + advanced therapies + genomics + clinical research

SOM

Identify the portion realistically accessible to a specific company based on:

• Product portfolio
• Technology
• Regulatory approvals
• Manufacturing capabilities
• Local partnerships
• Investment capacity
• Competitive positioning
• Saudi localization requirements

This approach produces a much more actionable commercial assessment than simply applying a global CAGR to Saudi Arabia.

What Are Saudi Biotechnology Buyers Actually Looking For?

This is where many generic industry reports miss the real client intent.

Pharmaceutical executives want to know:

• Which products should be localized?
• Which Saudi companies can become manufacturing partners?
• What technology-transfer opportunities exist?
• Which therapeutic areas receive strategic support?
• How can Saudi manufacturing support GCC exports?

CDMO executives want to know:

• What manufacturing capacity is missing?
• Who controls existing capacity?
• Which modalities have the highest outsourcing potential?
• Should we build, partner or acquire?

CRO executives want to know:

• Is clinical-trial activity increasing?
• Which therapeutic areas are receiving investment?
• Which hospitals and research centers should we target?
• What regulatory capabilities are required?

Investors want to know:

• Which biotechnology segments have government support?
• Where are the capability gaps?
• Which companies have strategic partnerships?
• Which infrastructure assets could become regional platforms?

Biotech founders want to know:

• Where can we conduct trials?
• Which hospitals can support development?
• Who can manufacture our therapy?
• How do we navigate SFDA requirements?
• Can Saudi Arabia become our GCC/MENA launch base?

These are high-intent commercial questions and they are much more valuable for lead generation than a generic “Saudi Arabia biotechnology market is growing” statement.

Regulatory Intelligence: Why SFDA Matters

The Saudi Food and Drug Authority is becoming a critical part of the biotechnology investment equation.

SFDA reported that its Reliance Pathway reduced study approval times by 74%, alongside the 83% increase in advanced-therapy and biotechnology clinical-trial applications in 2025.

SFDA has also introduced developments around clinical-trial systems and continues to issue regulatory guidance covering biological and biosimilar products.

For companies entering Saudi Arabia, regulatory intelligence therefore needs to be integrated into the commercial strategy not treated as a final-stage compliance activity.

Saudi Arabia vs Other Emerging Biotech Hubs

Saudi Arabia’s competitive advantage is developing differently from traditional biotechnology clusters.

Its proposition combines:

Government-backed investment + healthcare demand + localization + clinical infrastructure + manufacturing + genomics + regional export ambitions.

The National Biotechnology Strategy specifically seeks to create local end-to-end biomanufacturing capabilities and position Saudi Arabia for biologics and biosimilar exports.

That means the Kingdom is competing not only for pharmaceutical sales but also for:

• Manufacturing investment
• Clinical trials
• Technology transfer
• Biotech companies
• R&D activities
• Skilled talent
• Regional headquarters

2026–2030 vs 2030–2035: Where Will the Opportunity Move?

2026–2030: Capability Building

The immediate focus is likely to remain on:

• Manufacturing localization
• Clinical trials
• Biologics
• Vaccines
• Biosimilars
• Genomics
• Cell and gene therapy
• Technology transfer
• Workforce development

The emergence of Lifera and KFSH&RC’s advanced-therapy manufacturing capabilities illustrates this phase.

2030–2035: Scaling and Regionalization

As capabilities mature, the opportunity can increasingly shift toward:

• Commercial-scale biomanufacturing
• MENA exports
• Regional clinical trials
• Precision medicine
• Advanced therapy commercialization
• AI-enabled drug discovery
• Genomics-based healthcare
• Cross-border biotech partnerships

This is where Saudi Arabia’s biotechnology strategy could transition from localization to regional platform building.

The Real Saudi Biotechnology Opportunity

The strongest conclusion from the current data is not simply that Saudi Arabia’s biotechnology sector will grow.

It is that the structure of the opportunity is changing.

Saudi Arabia is building:

• A clinical research ecosystem.
• A biomanufacturing ecosystem.
• An advanced-therapy ecosystem.
• A genomics ecosystem.
• A technology-transfer ecosystem.

And increasingly, a potential MENA biotechnology export platform.

For companies evaluating the Kingdom, the winning question is therefore not:

“What is the Saudi biotechnology market size?”

The better question is:

“Where does Saudi Arabia have the largest capability gap between 2026 and 2035—and what can our company provide to close it?”

That is where the real commercial opportunity begins.

How Towards Healthcare Can Support Market Entry

For pharmaceutical, biotech, CDMO, CRO and healthcare technology companies evaluating Saudi Arabia, a useful market assessment should go beyond market size.

Towards Healthcare Research & Consulting can support decision-making across:

• Saudi Arabia biotechnology TAM/SAM/SOM
• Competitor benchmarking
• Company and partner identification
• Biomanufacturing opportunity assessment
• Clinical-trial intelligence
• Regulatory intelligence
• Technology-transfer opportunities
• Customer and buyer mapping
• Investment opportunity analysis
• Market-entry strategy
• 2030–2035 opportunity forecasting

If Saudi Arabia is part of your 2026–2035 expansion strategy, the next step is not simply estimating the opportunity it is identifying exactly where your company can win.